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INHERENT ANTICIPATION IN BIOTECHNOLOGY PATENTS
IN LIGHT OF INRE CRUCIFEROUSSPROUTLITIGATION
AND ELAN PHARMACEUTICALS
By
Brian Orr
© 2005, Chicago-Kent Journal of Intellectual Property
INTRODUCTION
Before a company invests in developing new technologies or new products that
would infringe patents held by others, the company must decide whether to attempt to
acquire a license or to risk litigation.1 If a company decides to purchase a patent license,
the company will greatly reduce its chances of exposure to litigation. 2 However, this
security comes at a cost, and not all patent holders are willing to license their patents. On
the other hand, if a company decides not to take a license, the company risks the
possibility of a patent infringement lawsuit. Ifjudgment is found against the company,
not only will damages likely result, but an injunction may be granted, and the company
may lose its entire investment.
Companies need to make a cost-benefit-risk analysis when determining whether
or not to take a license. This is especially true in the pharmaceutical industry. A recent
study by the Federal Trade Commission determined that from 1998-2000 generic drug
manufacturers sought to enter the market with a new generic version of a patented drug
before the patent expired approximately 20 percent of the time. 3 This is an increase of 18
percent from the 1980's. 4 If a patent is believed to be invalid, companies are more likely
to decide not to take a license. By establishing more definable standards for determining
whether a patent is anticipated, companies can more readily determine if a patent is in
fact invalid. Therefore, by establishing more definable standards for determining
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whether a patent is anticipated, companies can more capably decide whether to invest in a
license or risk litigation.
Recently, the United States Court of Appeals for the Federal Circuit has examined
inherency in two biotech cases.5 In In re CruciferousSprout Litigation, the court found
that certain properties of food products were inherent and, therefore, anticipated. 6 On the
other hand, in Elan Pharmaceuticals,Inc. v. Mayo Foundation,the Federal Circuit found
that there was no inherency when a prior patent gave only general instructions for gene
transfers between humans and animals. 7 In light of the recent In re CruciferousSprout
Litigation and Elan Pharmaceuticalsdecisions, the biotechnology industry is in need of a
clearer standard for inherency.
This note will examine the In re Cruciferous Sprout Litigation and Elan
Pharmaceuticalsdecisions and determine the impact they will have on the ability of
inventors to obtain valid biotech patents. Part I will give a general background of
inherency in patent law. Part II will outline the In re CruciferousSprout Litigationand
the Elan Pharmaceuticalsopinions. Part III will contain a list of factors that should be
helpful in determining if an element is inherent in a prior art reference for biotech patents.
Finally, Part IV will apply the factors to the facts in In re Cruciferous Sprout Litigation
and Elan Pharmaceuticals.
I. BACKGROUND OF INHERENCY
A. Patents Generally
Patents grant inventors of eligible inventions the right to exclude others from
making, using, selling, offering to sell or importing the patented invention. 8 After the
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patent term has expired, the invention enters into the public domain, and is available to
the public.
The Constitution grants Congress the authority to create a patent system, if
Congress so desires. 9 Congress has used its authority to create the 1952 Patent Act,
0
which provides the guidelines for the current U.S. patent law.'

B. Overview of Anticipation
Under the current patent statute, in order to obtain a patent, an invention must be
new, or in other words, novel." A patent can lack novelty if any of the circumstances
contained in 35 U.S.C. § 102 are fulfilled. 12 Commonly, a patent lacks novelty if the
invention claimed was in public use or on sale in the U.S. one year prior to the date the
patent application was filed, if the invention was known or used by others in the U.S.
before the invention was conceived, or if the invention was described in a printed
publication in any country one year prior to the date the patent application was filed. 13 If
14
an invention is not novel, it is considered anticipated.

For an invention to be anticipated, each and every element of the invention must
be found in a single prior art reference. 15 A prior art reference is anything from the past
or present that is known and available to the public. 16 The prior art reference must enable
one skilled in the art to make the claimed invention. 17 Although the prior art reference
must contain each and every element of the invention, the elements may be either express
or inherent. 10 An element is expressly disclosed if the prior art reference directly states
the element. An element is inherently disclosed if one skilled in the art could infer the
element. To prove inherency, additional sources apart from the prior art reference can be
18
used to demonstrate that one skilled in the art would have known the inherent element.
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If all the elements are either inherently or expressly found in a single prior art reference,
the patent is considered anticipated and invalid.
C. Policy Reasons for Inherency
The patent system encourages innovation, and novelty discourages inventive
activity that will not enrich the public knowledge.1 9 Novelty balances the interests of the
public and the inventor.

Novelty requires an inventor to secure his patent promptly and

only rewards the inventor with patent protection if he seeks such protection early. 21 This
encourages an inventor to file for a patent as soon as possible, which in turn enriches the
public knowledge.

22

Inherent anticipation serves two policy goals: First, it assures that patents do not
become too large with excessive details. An inventor may choose not to disclose all of
the information in a prior art reference, assuming that the omitted details were inherent
and one skilled in the art would inherently know what was not disclosed. However, it is
not necessary that one skilled in the art appreciate the inherent disclosure at the time the
prior art reference was made public. 23 Therefore, a second policy goal also exists.
Secondly, inherent anticipation coincides with the notion that an inventor should
only be granted patent protection for his development to the extent it advances public
knowledge. 24 If certain information has already been disclosed to the public inherently,
an inventor should not be granted patent protection for that information.
II. IN RE CR UCIFEROUS SPROUT LITIGATION AND ELAN
PHARMACEUTICALS, INC. V. MAYO FOUNDA TION
A. In re Cruciferous Sprout Litigation
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Johns Hopkins University owned three patents that described a method for
growing and preparing certain sprouts.

Particular spouts that are harvested at a specific

time contain higher levels of glucosinolate. 26 Foods with high levels of glucosinolates
produce Phase 2 enzymes in the human body; these enzymes help detoxify carcinogens,
thus reducing the risk of developing cancer. 27 Johns Hopkins licensed the patents to
Brassica Protection Products, LCC; Brassica then sued Sunrise Farms and others for
patent infringement. 2 8 As a defense, Sunrise Farms claimed that the patents were
anticipated.29
The court agreed with Sunrise Farms and invalidated the patents. 30 Numerous
prior art references identified the sprouts as edible. 3 1 Although these prior art references
did not mention glucosinolates or the potential of the sprouts to induce Phase 2
32

enzymes,

the court determined that high levels of gluscosinolates were present in

sprouts as long as sprouts have existed.33 Therefore, the gluconsinolates were inherent
characteristics disclosed by the prior references.3 4 The court concluded that because the
patents merely recognized a property inherently disclosed in prior art references, the
patents were anticipated.3
B. Elan Pharmaceuticals, Inc. v. Mayo Foundation
a. Facts
The prior art reference applied in this case was a patent granted to Dr. Michael
Mullan concerning transgenic mice. 36 Transgenic mice are created by combining mouse
DNA with mutated human genes. 37 These transgenic mice were developed so that the
mice would be susceptible to Alzheimer's disease. 38 The Mullan Patent disclosed various
procedures for making such transgenic mice. 39 However, Mullan did not produce any
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transgenic mice or determine which of the procedures would be effective in the
40
production of the mice.

Meanwhile, the Elan Patent described a procedure for the production of transgenic
mice, which are created by combining mouse DNA with a mutated human gene known as
the "Swedish mutation." 41 The "Swedish mutation" gene has an extremely high
incidence of early-onset Alzheimer's disease. 42 It is believed that the presence of a
protein fragment called beta-amyloid peptide (betaAP) in the brain induces Alzheimer's
disease. 43 It is understood that betaAP is formed by the separation of a protein produced
in the brain, called amyloid precursor protein (APP).4 4 In turn, the APP protein is split
into a protein fragment called amino terminal fragment (ATF-betaAPP), and an
enzyme. 45 The ATF-betaAPP protein fragment is larger and therefore easier to detect
than the betaAP molecule. 46 Not all mice will accept the "Swedish mutation" gene, but
those that do will have detectable levels of ATF-betaAPP in their brains. 47 The Elan
Patent only included mice with the presence of detectable levels of ATF-betaAPP. 48
b. The Federal Circuit's Holding
Mayo argued that the Mullan Patent inherently disclosed transgenic mice with
detectable levels of ATF-betaAPP because under the Mullan Patent some percentage of
the transgenic mice produced would have been expected to produce detectable levels of
ATF-betaAPP. 49 The court disagreed, determining that the Mullan patent was merely
general instructions to transfer genes between humans and animals. 50 The court held that
such general instructions did not anticipate the second patent and offered no more than a
51
starting point for further experimentation.
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c. Judge Dyk's Dissenting Opinion
Judge Dyk dissented from the majority opinion. 52 Judge Dyk asserted that the
Mullan Patent included transgenic mice having the Swedish mutation form of APP, and
that a mouse containing APP would produce a detectable amount of ATF-betaAPP. 53
Although only a small amount of the transgenic mice produced under the Mullan Patent
would express the Swedish form of the APP, all the mice that did contain the APP would
produce ATF-betaAPP.5 4 Judge Dyk reasoned that the Mullan Patent therefore
anticipated the Elan Patent, and that the Elan Patent should be declared invalid. 55

III. FACTORS FOR BIOTECH PATENTS
The doctrine of inherent anticipation applies in three basic circumstances: 56 The
first situation occurs when the prior art reference describes an inherent property. 57 The
second occurs when the prior art reference contains an inherent use.

The third incident

59
occurs when the prior art reference contains an inherent method of practicing the art.

Since each of these circumstances requires different determinations of whether a patent
has been anticipated, this article has developed separate factors for inherent properties,
inherent uses and inherent methods.
A. Inherent Properties
A patent can be anticipated if a prior art reference contains the same properties.
The prior art reference need not expressly describe every property; instead, these
properties may be inherently disclosed. 60 The cases, Schering Corp. v. Geneva
Pharmaceutical,Inc. and In re Omeprazole PatentLitigation, demonstrate how
anticipation of inherent properties applies to the biotech industry.
1. Schering Corp. v. Geneva Pharm., Inc.
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In February 1984, Schering Corporation filed and was granted a patent (the '233
Patent) for the drug loratadine, which is used to treat allergic reactions. 61 When humans
ingest loratadine, DesCarboethoxylLoratadine (DCL) is produced.62 However, at the
time the application was filed, one skilled in the art would not have realized that the
ingestion of loratadine would produce DCL. 63 Later, Schering and Geneva
Pharmaceuticals performed clinical studies that demonstrated that DCL is produced when
loratadine is ingested.64 Subsequently, Schering also obtained a separate patent (the '716
Patent) for DCL.65
The court determined that although the '233 Patent did not expressly describe
DCL, the '233 Patent still anticipated the '716 Patent because DCL is an inherent
function of the '233 Patent. 66 The court stated that "the discovery of a previously
unappreciated property of a prior art composition, or of a scientific explanation for the
prior art's functioning, does not render the old composition patentably new to the
discoverer." 67 The court concluded that, although artisans of ordinary skill in the art did
not recognize the inherent function of DCL, the production of DCL after the ingestion of
loratadine is an inherent function of the use of loratadine, and therefore the '716 Patent
68
was anticipated by the '233 Patent.

2. In re Omeprazole Patent Litigation
In 1981, Astra was granted a patent (the '431 Patent) for the chemical compound
omeprazole, which Astra sells under the name Prilosec TM . 69 Scientists at Astra later
determined that when omeprazole is administered to humans it produces sulphenamides,
70
which inhibit the enzymes responsible for gastric-acid secretion in the stomach lining.
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In 1987, Astra was granted a patent (the '499 Patent) for sulphenamide compounds and
the administration of sulphenamide.

71

When the '431 Patent expired in October of 2001, Genpharm and Chemior
desired to sell generic versions of omeprazole. 72 Astra claimed that since the ingestion of
omeprazole causes sulphenamides to form in the body, Genpharm and Chemior's
73
proposed plan to manufacture omeprazole would infringe the '499 Patent.

The court determined that the '499 Patent was an attempt to patent "a scientific
explanation for the prior art's function," which is unpatentable. 74 The court held that the
prior art reference inherently anticipated any claim for the production of sulphenamides
75
formed after the ingestion of omeprazole.

3. Summary and Factors for Inherent Properties
In both Schering Corp. and In re Omeprazole drug companies attempted to patent
later discoveries from previously-held patents. If the inherent properties of the previous
patents were allowed to be patented, this would result in the extension of the original
patent's monopoly.
To prevent inherent properties from being patented, the factors the courts should
take into consideration in determining whether a prior art reference inherently anticipates
a subsequent claimed invention are:
(1)

whether the inherent property was known when the prior art
reference was published;

(2)

whether the inherent property is always produced;

(3)

whether the prior art reference gives the public the benefit of the
inherent property that the patent is attempting to claim.
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Starting with the first factor -- whether the inherent property was known when the
prior art reference was published -- strengthens a claim of anticipation. If the inherent
property was known at the time the prior art reference was published, this would indicate
that one skilled in the art could infer the inherent property. On the other hand, the patent
holder in both Schering Corp. and In re Omeprazole did not know that their respective
drugs produced a specific result when ingested by humans. 76 However, when the
companies later discovered and tried to patent the specific results, those patents were
found to be anticipated and invalid.77 Therefore, a patent can still be anticipated if the
inherent property was not known when the prior art reference was published because the
knowledge of one skilled in the art may have increased since the prior art reference was
published.
Turning to the second factor, if the inherent property is not always produced
following the instructions of the prior art reference, this decreases the possibility that one
skilled in the art would discover the inherent property in the prior art reference,
weakening a claim of anticipation.
Additionally, possibilities or probabilities are not enough; the inherent property
must be certain to occur from the information disclosed in the prior art reference. On the
other hand, a claim is stronger if the inherent property is always produced. Under these
circumstances, one skilled in the art would be more likely to discover the inherent
property and attribute the inherent property to the prior art reference.
Finally, if, prior to the filing of a patent application, a prior art reference already
disclosed the inherent property to the public, the public will not be enriched by the patent
application. The U. S. patent system essentially grants inventors a monopoly in exchange

for publicly disclosing how to produce their invention. On the other hand, if the inherent
property has not been previously made known to the public, the inventor has disclosed
something new to the public and, in turn, should be granted a patent. Yet, if the public
already knows of the inherent property, the new patent has not revealed anything to the
public and the inventor should not be granted a patent.
B. Inherent Uses
A patent can also be anticipated if the prior art reference contains an inherent use.
Since artisans may not disclose every use for an invention, a use may be inherent in a
prior art reference.7 8 The following cases, MEHL/Biophile Int. Corp. v. Milgraum and In
re Woodruff, establish how the anticipation of inherent uses relates to patent law.
1. MEHIBiophile Int. Corp. v. Milgraum
MEHL/Biophile held a process patent for the removal of hair using a Q-switched
laser. 79 MEHL/Biophile claimed that Milgraum and others infringed their patent, while
Milgraum contended that MEHL/Biophile's patent was anticipated. 80 Milgraum relied
upon two prior art references in claiming anticipation - a manual for the RD-1200 laser
that described the removal of tattoos using a Q-switched laser, and the Polla article which
81
described using a Q-switched laser to remove hair from guinea pigs.

The court concluded that the RD-1200 manual did not anticipate the patent
because it did not teach all the claim limitations. 82 Since the RD-1200 manual dealt with
83
the removal of tattoos, the manual did not discuss aligning the laser over hair follicles.

The court noted that although the manual did not discuss the removal of hair, it was
84
possible that a person following the manual could align the laser over a hair follicle.
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However, the court determined that such an "occasional result" was not inherent, and the
85
manual did not anticipate the patent.

The court reached a different result with the Polla Article. The court concluded
that the Polla Article inherently taught the vertical alignment of a Q-switched laser over a
hair follicle, finding the difference between the removal of human hair and guinea pig
hair irrelevant to the anticipation analysis. 86 Also irrelevant was the fact that the Polla
Article did not discuss the removal of hair as a goal of the study. 87 These findings led the
88
court to hold that the Polla Article anticipated MEHL/Biophile's patent.

2. In re Woodruff
Woodruff filed a patent application that described a process to prevent the growth
of fungi on fresh fruits and vegetables by modifying the atmosphere. 89 Both the Patent
and Trademark Office and the Board of Appeals rejected the application, and Woodruff
appealed. 90 In rejecting Woodruff s patent application, the Board of Appeals relied upon
a sole prior art reference, a U.S. Patent issued to McGill. 91 The McGill patent disclosed a
process to maintain the fresh appearance of leafy and head vegetables stored over an
extended period of time. 92 The McGill Patent was designed to prevent bacterial growth
and discoloration, but the McGill Patent made no mention about the growth of fungi.93
Both the Woodruff and McGill storage methods used a modified atmosphere and a lower
temperature.

94

The court determined that one of the purposes of the McGill Patent, preventing
discoloration, would inherently include fungal growth.95 Therefore, the court concluded
96
that the McGill patent contained the "new use" that Woodruff desired to patent.

3. Summary and Factors for Inherent Uses
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The plaintiffs in both MEHL/Biophile and In re Woodruff wanted to patent a
process or a compound based upon the development of a new use for the process or
compound. Inventors may be granted a method patent for the development of a new use.
However, a process or a compound patent generally has a greater scope of protection than
method patents, and so should only be granted in limited circumstances.
In determining if a process or compound patent is warranted, the courts should
analyze:
(1)

whether all the same steps are used in the prior art reference;

(2)

whether the use only occasionally results from the steps disclosed
in the prior art reference.

Beginning with the first factor, if all the same steps are used in both the prior art
reference and the later filed patent, only a method patent should be granted for a nonpreviously disclosed use. In MEHL/Biophile, both the patent and the prior art reference
discussing hair removal of guinea pigs contained the same steps to use a laser to remove
hair. 97 Similarly, in In re Woodruff, the same process for storing vegetables by
modifying the atmosphere and lowering the temperature was used in both the prior art
reference and the patent. 98 Both the patents in MEHL/Biophile and In re Woodruff were
found invalid although an inherent use for the processes explained in the prior art
references was later developed. 99 Alternatively, if the prior art reference and the patent
contain different steps to achieve a different use, this would indicate that the patent is not
anticipated.
Addressing the second factor, if the use described in the patent only occasionally
results from the process disclosed in the prior art reference, the patent should not be
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anticipated. The MEHL/Biophile court found the possibility of hair being removed by
accidentally aligning a laser over a hair follicle during the removal of a tattoo was an
occasional result. 100 An undiscovered, occasional result does not enrich the public
knowledge. 1 1 If a subsequent inventor discovers an occasional result and discloses this
information through a patent, this would weaken a claim of anticipation. Alternatively, if
the use disclosed in the patent always occurs under the process described in the prior art
reference, the patent would not enrich the public knowledge, and claim of anticipation
would be strengthened.
C. Inherent Methods
Finally, a claim can be anticipated if it discloses a substantially similar method to
the method claimed in the prior art reference. Even if the prior art reference does not
explicitly state the same method, a method can still be inherent. 10 2 The following cases,
In re Baxter Travenol Labs, Glaxo, Inc. v. Novopharm Ltd., and Glaxo Wellcome, Inc. v.
Ben Venue Laboratory,Inc., demonstrate how the anticipation of inherent methods
applies to the biotech industry.
1. In re Baxter Travenol Labs
Baxter filed a patent application for an invention for the collecting, processing,
and storing of blood using a multiple-blood-bag system.I13 The invention used the first
bag for the collection and storage of red blood cells and at least one additional bag for the
collection and storage of another blood component. 104 The first bag was made of the
plastic polymer di-2-ethylmexyl phithalate (DEHP), while the second bag was made of a
different plastic. 105
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In October 1969 a Baxter employee wrote a prior art reference, "Contract PH 4367-1403; Final Technical Progress Report; Development of Containers for Preservation
of Frozen Blood Components."' 106 This document described a new blood-bag system that
used a bag made of polyvinyl chloride (PVC) as the donor bag and a secondary bag made
of Teflon. 107 The document described the blood-bag system as very similar to another
blood container manufactured by Baxter at that time. 108 The document did not expressly
refer to the use of DEHP, but at the time the prior document was written, all of the bloodbag systems Baxter manufactured contained DEHP.10 9
Because the prior document referred to a blood-collection system manufactured
by Baxter and the systems manufactured by Baxter contained primary bags comprised of
DEHP, the court determined that one skilled in the art would have known that the similar
blood-collection system referred to contained a primary bag consisting of DEHP.110
Therefore, the court concluded that the patent application was anticipated."'

276

2. Glaxo, Inc. v. Novopharm Ltd.
In July 1977, Glaxo filed a patent application that described a method for the
production of ranitidine hydrochloride (Form 1).112 For three years after the filing of the
patent, Glaxo experimented with the production of ranitidine hydrochloride using
procedures not disclosed in the 1977 patent.113 In April 1980, using one of the new
procedures, Glaxo produced a new form of ranitidine hydrochloride (Form 2). 114 In
115
1981, Glaxo filed a patent for Form 2 in the United States.

Novopharm sought to invalidate Glaxo's 1981 patent by claiming it was
anticipated by the 1977 Glaxo patent.116 Novopharm argued that Form 2 was inherent in
the patent filed in 1977.117 Novopharm followed the 1977 patent to manufacture
ranitidine hydrochloride, but made some minor changes to the procedure.'

However,

these changes were not outside the teachings of the 1977 patent for one skilled in the art,
and the court found these changes acceptable. 119
The court then determined that the method for production of ranitidine
hydrochloride disclosed in the 1977 patent sometimes produced Form 1 and sometimes
produced Form 2. 12 Therefore, the procedures for making ranitidine hydrochloride in
the 1977 patent did not invariably result in the production of Form 2.121 Because
possibilities or probabilities cannot establish inherency, the court concluded that
22
Novopharm failed to prove inherency.l

3.

Glaxo Wellcome, Inc. v. Ben Venue Laboratory, Inc.

Glaxo developed an intravenous, injectable version of the drug Zantac TM , which is
used to treat ulcers. 12 3 Glaxo filed for and was granted a patent (the '658 Patent) for the

intravenous form of Zantac TM

12 4

24

The patent described the process for manufacturing
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Zantac TM using a pH level between 5.0 and 6.0.125 A pH level between 5.0 and 6.0
increased the chemical stability of ZantacTM , which in turn increased the shelf life of the
drug. 126 Glaxo continued to study the chemical stability of Zantac TM , and later
determined that Zantac TM was most stable at a pH of 7.0.127 In 1984, Glaxo filed a patent
for intravenous Zantac TM manufactured at a pH of 7.0. 12

Initially, the Patent and

Trademark Office rejected the patent application as being both anticipated and obvious,
29
but upon reconsideration, the patent (the '790 Patent) was granted. 1

The '658 Patent did not expressly state a pH level of 7.0.130 Therefore, to prove
anticipation Ben Venue had to show that one skilled in the art would realize that a pH of
7.0 was inherent. 13 1 The '658 Patent did teach that the pH level affects chemical stability,
but the court concluded this disclosure was merely a starting point for further
experimentation. 132 Determining that one skilled in the art using the '658 Patent would
not have recognized that the chemical stability of injectable Zantac TM could be increased
when a pH level of 7.0 was used, the court concluded that the '658 Patent did not
33
inherently anticipate the '790 Patent. 1

4. Summary and Factors for Inherent Methods
In the cases discussed above, the plaintiffs wanted to patent a process that was at
least partially disclosed in a prior art reference.
In determining what constitutes an inherent method courts should analyze:
(1)

what the industry or corporate standard was at the time the prior art
reference was published;

(2)

whether the process disclosed in the prior art reference always
produces the result sought to be patented;
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(3)

whether the amount of experimentation required to discover the
subsequent inherent method was "undue."

Beginning with the first factor, determining what the industry or corporate
standard was at the time the prior art reference was published, helps clarify the
knowledge of one skilled in the art. In, In re Baxter Travenol Labs, all bags
manufactured by Baxter at the time the prior art reference was published were made of
the same material. 134 Baxter later filed a patent claiming a bag made of that material, and
the In re Baxter Travenol Labs court held that the patent was anticipated by the prior art
reference. 135 One skilled in the art would have known of the industry or corporate
standard, even if the standard were not disclosed in the prior art reference. Therefore, if
the inherent method was the industry or corporate standard at the time the prior art
reference was published, this would indicate that one skilled in the art would have known
of the inherent method, and a claim of anticipation would be strengthened. Even if the
industry or corporate standard were not the inherent method, this would not necessarily
weaken a claim of anticipation if the knowledge of one skilled in the art has increased
since the publication of the prior art reference.
Turning to the second factor, a claim of anticipation may be strengthened or
weakened by the consistency of the results of the prior art reference. Consistent results
increase the chance that the one skilled in the art would have discovered the inherent
method and already disclosed the inherent method to the public, strengthening a claim of
1 36
anticipation. Alternatively, occasional results like those in Glaxo, Inc. v. Novopharm

are not enough to show that one skilled in the art would discover the inherent property
from the prior art reference, weakening a claim of anticipation.
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Addressing the final factor -- the amount of subsequent experimentation required
to discover an inherent method -- would indicate inherency of the method in the prior art
reference. If an undue amount of experimentation were required to develop the inherent
method, the public did not previously know of the inherent method, and the inventor
should be granted a patent. In Glaxo Wellcome, Inc. v. Ben Venue Laboratory,Inc.,
Glaxo developed a more stable version of a drug that was outside the teachings of the
prior art reference. 137 The Glaxo Wellcome court found that the prior art reference was
merely a starting point for further experimentation, and the prior art reference did not
anticipate the patent.138 Like the prior art reference in Glaxo Wellcome, if an undue
amount of experimentation were required to develop the inherent method, this would
weaken a claim of anticipation.

IV. APPLICATION OF FACTORS
Applying the factors put forth in this note to the facts in, In re Cruciferous Sprout
Litigation and Elan Pharmaceuticalswill help illustrate how the factors will give a
clearer standard for inherent anticipation. Since inherency is a question of fact, the trier
of fact should apply these factors.
A. Application of the Factors to In re Cruciferous Sprout Litigation
In, In re Cruciferous Sprout Litigation an inherent property was claimed to be
anticipated. Like the drugs in Schering Corp. v. Geneva Pharmaceuticalsand In re
Omeprazole Patent Litigation,the patent in, In re CruciferousSprout Litigation claimed
a property of the sprouts that was inherent in the sprouts themselves. Because an inherent
property was claimed to be anticipated, the factors for inherent properties should be
applied. These factors include: (1) whether the inherent property was known when the
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prior art reference was published; (2) whether the inherent property is always produced;
and (3) whether the prior art reference gives the public the benefit of the inherent
property that the patent is attempting claim.
The prior art references in, In re CruciferousSprout Litigation identified the
sprouts claimed in the patent as edible. 139 These prior art references did not disclose the
beneficial effects of the glucosinolates contained in the sprouts; 140 therefore, the inherent
property of the production of Phase 2 enzymes from the ingestion of the glucosinolates in
the sprouts was not known when the prior art references were published. Since the
inherent property was not known, this factor would weigh against a finding of inherent
anticipation.
14 1
Sprouts have contained glucosinolates as long as sprouts have existed.

Although certain types of sprouts contain higher levels of glucosinolates,

142

when the

sprouts with higher levels of glucosinolates are consumed, Phase 2 enzymes are always
produced in the human body. Therefore, the inherent property of the production of Phase
2 enzymes from the ingestion of the glucosinolates in the sprouts is always produced
when the sprouts listed in the patents are grown and eaten. Because the inherent property
is always produced, this factor would weigh in favor of a finding of inherent anticipation.
The prior art references in, In re CruciferousSprout Litigation did not explain that
certain varieties of sprouts contain glucosinolates, which produce Phase 2 enzymes,
which, in turn, reduces the risk of developing cancer. 143 However, by following the prior
art references, one skilled in the art would be able to reduce the risk of developing cancer
by cultivating and consuming the certain types of sprouts listed in the patents at issue.
Therefore, the public already had the benefit of the inherent property that the patent was

attempting to claim, and this factor will weigh in favor of a finding of inherent
anticipation.
After applying the facts from In re Cruciferous Sprout Litigation, two of the three
factors weigh in favor of finding inherent anticipation. Therefore, the patents in, In re
CruciferousSprout Litigation should be considered anticipated by the prior art references
44
and held invalid. The Federal Circuit reached the same conclusion. 1

B. Application of the Factors to Elan Pharmaceuticals
Rather than an inherent property, an inherent method was claimed to be
anticipated in Elan Pharmaceuticals. Like the prior art references in In re Baxter
Travenol Labs, Glaxo, Inc. v. Novopharm Ltd., and Glaxo Wellcome, Inc. v. Ben Venue
Lab. Inc., the process disclosed in the patent in Elan Pharmaceuticalswas at least
partially disclosed in a prior art reference. Because an inherent method was claimed to be
anticipated, the factors for inherent methods should be applied. These factors include: (1)
what the industry or corporate standard was at the time the prior art reference was
published; (2) whether the process disclosed in the prior art reference always produces
the result sought to be patented; and (3) whether the amount of experimentation required
to discover the subsequent method was "undue."
No transgenic mice were produced using the prior art reference, the Mullan
Patent. 14 5 Since no mice were produced, no industry or corporate standard for the
production of transgenic mice would have existed when the Mullan Patent was published.
Therefore, what the industry or corporate standard was at the time the prior art reference
was published would not apply.
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The methods for producing transgenic mice disclosed in the Mullan Patent were
unpredictable and had low success rates. 146 However, under the Elan Patent, the mice are
screened for detectable levels of ATF-betaAPP.1 47 This screening determines whether
the Swedish DNA has been transferred to the mice, and in turn whether the mice will
produce Alzheimer's disease.148 Unlike the Elan Patent, the process disclosed in the
Mullan Patent does not always produce the results sought to be patented. Therefore, this
factor would weigh in against a finding of inherent anticipation.
The Mullan Patent described methods for making transgenic mice, but did not
49
disclose the production of transgenic mice having detectable levels of ATF-betaAPP. 1

When the Mullan Patent was filed, no one (1) had made a transgenic mouse that
contained the Swedish gene; (2) knew whether the Swedish gene would be accepted by
mouse DNA; or (3) knew whether levels of ATF-betaAPP would be detectable in
mice. 150 Given the amount of experimentation required, after the Mullan Patent, to
produce transgenic mice with detectable levels of ATF-betaAPP, the amount of
experimentation required to discover the subsequent method should be considered
"undue." Therefore, this factor should weigh against a finding of anticipation.
After applying the facts from Elan Pharmaceuticalto the factors put forth in this
note, two of the three factors weigh against a finding of inherent anticipation. Therefore,
the patents in Elan Pharmaceuticalshould not be considered anticipated by the prior art
reference and held not invalid. The vacated Federal Circuit decision reached the same
conclusion. 151
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CONCLUSION
The factors put forth in this note give legal practitioners and the biotechnology
industry a clearer standard for inherency. Applying the factors to relevant cases will help
lawyers and judges better determine whether a patent has been inherently anticipated.
Additionally, the factors will allow businesses to more readily determine whether a patent
is invalid, and in turn, help businesses decide whether to acquire a license or risk
litigation.
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